Lantern Pharma Expands Precision Oncology Collaboration with the National Cancer Institute - Accelerating Path to First in Human Clinical Trials for Drug Candidates LP-184 & LP-284
Previous
Previous
Lantern Pharma rises 9% on team up with National Cancer Institute for drug candidates
Next
Next